Lv1
20 积分 2021-01-21 加入
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
7个月前
已完结
Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab
7个月前
已完结
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis
7个月前
已完结
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial
7个月前
已完结
The role of OX40 ligand/OX40 axis signalling in atopic dermatitis
7个月前
已完结
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
7个月前
已完结
ACG Clinical Guideline Update: Ulcerative Colitis in Adults
7个月前
已完结
Combination biologic therapy for ulcerative colitis
7个月前
已完结
Combination therapy in inflammatory bowel disease: Current evidence and perspectives
7个月前
已完结
皖公网安备34019202002308
